For Scientists

More Results (Public Deliverables)

Within EU-funded Horizon 2020 projects, ‘Deliverables’ are major outputs that must be produced at a defined time point during the project. This includes, for example, the project website itself, a study protocol, detailed information on the progress of a specific task, a research manuscript, or another important “building block”. As soon as such a deliverable has been completed, a detailed deliverable report is required to be submitted to the European Commission (EC). While some deliverables are confidential, the ones shared here are publicly accessible (in rare cases and only when necessary, confidential information has been censored in the PDFs below).

D3.1 Report on acquired proteomics data 
This report presents the acquisition, quality assessment, and initial analysis of mass spectrometry-based proteomics data from plasma, urine, stool, and intestinal mucosa samples of the MUCOSA-PREDICT cohort, identifying potential protein biomarkers associated with disease progression and the development of acute-on-chronic liver failure (ACLF).

D3.2 Report on lipidomics and bile acids data 
This document presents the acquisition, quality assessment, and preliminary analysis of lipid mediator and bile acid profiles in plasma and stool samples from the MUCOSA-PREDICT cohort, highlighting differences in inflammatory lipid mediators between clinical courses of decompensated cirrhosis and providing data for further investigation of disease progression and acute-on-chronic liver failure (ACLF).

D3.3 Report on histological data of the gut barrier 
This report summarises the histological assessment of intestinal barrier integrity in patients with decompensated cirrhosis from the MUCOSA-PREDICT cohort, using tissue biopsy analysis, immunohistochemistry, and automated image quantification to investigate gut mucosal alterations and their associations with disease severity, bacterial translocation, and clinical outcomes.

D3.4 Report on metabolomics data 
This deliverable describes the acquisition and analysis of metabolomics data from serum, urine, and stool samples of the MUCOSA-PREDICT cohort, identifying metabolic signatures associated with disease severity and the development of acute-on-chronic liver failure (ACLF), while also investigating potential biomarkers for predicting patients’ response to albumin treatment.

D4.9 Multi-omic data analysis software public release 
This report summarises the development and public release of Multi-Omics for Relationships in Phenotypes and Health (MORPH), a software package integrating multi-omics data analysis and machine learning workflows to investigate disease associations, discover biomarkers, and support the prediction of disease progression and treatment responses in patients with advanced liver disease

D7.1 Final version of study protocol to be approved by ethics committee(s) 
Here, we share the finalised study protocol for the MICROB-PREDICT ALB-Trial, a multicentre, randomised, double-blind, placebo-controlled clinical trial designed to validate predictive biomarkers for personalised albumin treatment in patients with decompensated cirrhosis, detailing the study design, patient eligibility criteria, clinical endpoints, safety measures, and consultations with scientific, patient, and regulatory stakeholders in preparation for ethical approval.

D7.2 Registration number of clinical study in a WHO- or ICMJE-approved registry 
This deliverable documents the successful registration of the MICROB-PREDICT ALB-TRIAL in the publicly accessible ClinicalTrials.gov registry (identifier: NCT05056220), outlining the registry selection process, compliance with WHO and ICMJE registration requirements, and publication of key study information to ensure transparency and accessibility of the clinical trial.

D7.4 Posting results for the primary endpoint in the study registry (coming soon)

D7.6 Personalised treatment guidelines (coming soon)

D8.1 Policy for integrating the six agendas (ethics, gender equality, public engagement, governance, scientific education and open access) of responsible research and innovation
The goal of this policy document is to define the agendas of Responsible Research and Innovation (RRI) and ways of implementation within MICROB-PREDICT. Governance, ethics, gender equality, public engagement, open access and scientific education as the agendas of RRI are defined here, offering measures for implementation.

D8.2 Information and Informed Consent template for participation of human beings for using biological samples of human origin in research and for the use of personal data in research
This document provides a template for the use of human biological samples and personal data in biomedical research. It could be used as guidance or can be adapted to support the templates of each research institution involved.

D8.3 Public engagement strategy to design MICROB-PREDICT along with the need of patients
The goal of this policy document is to provide a framework of public engagement in research in MICROB-PREDICT, and to review the best approaches to patient involvement, as well as its benefits and costs. We summarise the Responsible Research and Innovation approach, define what public engagement entails, the different actors, tools and methodologies, and give recommendations.

D8.4 Codes of conduct applicable and research integrity policy including publications in journals
This document analyses the current codes of good conduct published by each member of the MICROB-PREDICT project, discusses what is included, any references to national or international guidelines, how easily accessible the relevant information is from the home page and the general usefulness of the document for the members of the institutions themselves and the public. At the end, there are 10 recommendations of useful points that each code of conduct should include.

D8.5 Model describing typical treatment paths in decompensated cirrhosis
In order to estimate how new tests that enable physicians to distinguish between patients that are low vs. high risk, and patients that respond vs. do not respond to treatments, we develop a benchmark model where the patient can be in one of four states: Cirrhosis, Decompensation, Acute Chronic Liver Failure and Death. The model includes information about the probability of going from one state to another, as well as the costs and quality of life in patients in each state. Knowing that a patient is high risk and/or a good candidate to respond to certain treatments, it is possible to avoid or delay progression to more severe states. These models will be used to calculate costs and benefits of the different interventions compared to the standard treatment when the data for the effectiveness of the tests becomes available at a later stage in the project.

D8.6 Implementation of an economic evaluation model in a software package
This deliverable describes the implementation of an app that implements an economic evaluation – calculations of costs and benefits – of a diagnostic test for response to Albumin treatment for patients with liver cirrhosis and shows how to use the model and the software to conduct an economic evaluation.

D8.7 Checklist for participants to assure informed consent / other mechanisms for those unable to give a written consent
The document includes a proposal of a checklist for participants and for researchers in biomedical research focused on participant information and the consent process to ensure that the project complies with the ethical and legal standards applicable. It is designed to ensure the free, informed and voluntary consent of participants, including those unable to consent and who need a legal representative.

D8.8 Manuscript on costs and benefits of new diagnostic tools (coming soon)

D9.2 Go-online of the public project website 
This report explains the development and launch of the MICROB-PREDICT public website, providing information on the project’s objectives, consortium, research activities, publications, and events, with dedicated sections for scientists, patients, healthcare professionals, and the general public.

D9.3 Project brochure and professional templates 
Here, we describe the development of standardised communication and dissemination materials, including a project brochure, letterhead, PowerPoint presentation, and scientific poster templates, to ensure consistent visual identity and professional communication of MICROB-PREDICT activities and objectives.

D9.4 First patient and layman event 
This deliverable reports on the first MICROB-PREDICT online patient event, organised in collaboration with the European Liver Patients’ Association (ELPA) on 8 July 2020, which introduced the project’s objectives, the ALB-TRIAL, and potential implications for cirrhosis management while promoting patient engagement and collaboration with national patient organisations.

D9.5 Dissemination activity at IHMC congress in Barcelona 2020 
This PDF reports on MICROB-PREDICT’s scientific contributions to the virtual International Human Microbiome Consortium (IHMC) Congress in June 2021, including four scientific presentations and four posters, alongside accompanying website and social media communication activities and their dissemination reach and impact.

D9.6 Brochure to inform in brief about MICROB-PREDICT for participants involved in the clinical study 
Here, we present the development of a patient-oriented information brochure explaining the MICROB-PREDICT project and its ALB-TRIAL, including the study’s objectives and personalised albumin treatment approach, to inform prospective clinical trial participants and their relatives.

D9.7 Second patient and layman event
This deliverable describes and summarises the second online patient education event, jointly organised by ELPA, EF CLIF andconcentris for the MICROB-PREDICT, DECISION, and A-TANGO liver projects on 9 June 2021, highlighting current treatment options, research needs, biomarker development, and emerging personalised therapeutic strategies for decompensated cirrhosis and acute-on-chronic liver failure (ACLF).

D9.9 Consensus-conference for the use of Microbiome-derived markers in liver disease 
This report documents the organisation, implementation, and outcomes of the MICROB-PREDICT Consensus Conference held on 27 May 2026 during EASL Congress in Barcelona, bringing together more than 100 participants to discuss expert consensus on microbiome-based mechanisms, biomarkers, patient stratification, and therapeutic response in decompensated cirrhosis and acute-on-chronic liver failure (ACLF). The conference built on an international Delphi survey and contributed to the development of consensus-based recommendations for future research and clinical practice.

D9.10 Video explaining new knowledge on the role of the human microbiome on liver disease, AD and ACLF 
This deliverable presents a series of 18 educational videos communicating key MICROB-PREDICT research findings on the human microbiome, liver cirrhosis, acute decompensation (AD), and ACLF. Nine scientifically oriented videos and nine accessible patient-focused interviews explain advances in biomarker discovery, disease mechanisms, patient stratification, and treatment approaches, supporting the dissemination of project results to scientists, patients, and the general public.

D9.12 Updated clinical practice guideline on cirrhosis and translation for layman 
Here, we state and explain 11 expert consensus-based recommendations for improving research, patient stratification, risk prediction, and therapeutic decision-making in decompensated cirrhosis and ACLF, developed through a two-round international Delphi process involving 137 experts from 27 countries. It also includes accessible lay summaries and graphical materials translating key MICROB-PREDICT findings into understandable information for patients, relatives, and the general public.